Labiotech.eu

News and Trends 9 Jun 2015

Apitope’s peptide to take on Haemophilia A

Apitope’s pre-clinical candidate ATX-F8-117 has been granted Orphan Drug Status by the US FDA for the treatment of Haemophilia A. The drug candidate already obtained an Orphan Drug Designation by the European Medical Agency last year. The compound also awakened the interest of Abzena, which works with Apitope to design the candidate. Haemophilia A is […]

June 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jun 2015

Kurma Partners announces the launch of its third fund Kurma Diagnostics

Kurma Diagnostics (KDx), the first Venture Capital fund dedicated to financing early-stage European innovative Diagnostic projects and companies, is here to stay. The firm Kurma Partners, author of this initiative, has received the support from several European and French institutions. The fund has raised €33 Million in its first fundraising round. KDx is a venture […]

June 9, 2015 - 2 minutesmins - By Nicolas Sainte-Foie

News and Trends 8 Jun 2015

An Easy Solution to Lower the Time and Costs of Clinical Trials

With the technology advances we have seen in the last 10 years, it’s hard to believe that, only 50% of clinical trials are using Electronic Data Capture (EDC), whilst the other 50% are still being run on paper and in Excel spreadsheets. Why is this adoption rate so low? The answer lies in the cost and […]

June 8, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 8 Jun 2015

Biosimilars will land in Poland thanks to a European loan

Biosimilars will have their Polish guarantor. Polpharma, the largest Polish producer of medicines, is the first benefactor of a €45M loan granted by the European Investment Bank. The loan was granted for research and development of biosimilars and is part of InnovFin, the EU fund for innovators. The production of biosimilars involves numerous difficulties in […]

June 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jun 2015

Review: The Emerging Field of Bioluminescence

Thanks to the synthetic biology revolution, bioluminescence is now moving from a curious natural trait to an interesting research field that could soon arrive to the market. Bioluminescence’s impulsors aim at replacing electric lighting. Sounds good, but which are the most advanced projects right now? Will bioluminescence really have an impact on the lighting market and […]

June 8, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 5 Jun 2015

NuCana’s potent anti-cancer completed Phase I/II

Good news just keeps on coming from ASCO Annual Meeting. Edinburgh-based NuCana presented in two abstracts the last data from Acelarin, the company’s first anti-cancer agent, produced on its ProTide developing platform. ProTides are NuCana’s new class of anti-cancer agents, which are specifically designed to overcome key cancer resistance mechanisms that severely limit the action […]

June 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 5 Jun 2015

Novartis declines Gamida’s buyout deal for the second time

Novartis has rejected the Israeli biotech Gamida Cell… again. The Big Pharma has decided not to carry out its option on the Israel-based company. The transaction would have meant a €535.5M deal but it won’t happen, despite Gamida having fulfilled the milestones of the bilateral agreement. Novartis, however, will maintain their collaboration. It is the second time […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 4 Jun 2015

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

MorphoSys has presented at ASCO optimistic results of MOR202’s phase I/IIa study, a candidate treatment against multiple myeloma. The project was doubted after Celgene’s abandon, but now, safety and efficacy data have shown that there is nothing to worry about. MOR202 is a fully human monoclonal HuCAL antibody targeting CD38, a highly expressed and validated target […]

June 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

[Update] AstraZeneca to buy a CAR-T expert?

[Update] Bloomberg announced that they make wrong conclusions from their discussion with AstraZeneca’s CEO Pascal Soriot. The CEO was not talking about the specific acquisition of Juno Therapeutics but about a potential acquisition of a CAR-T expert. Juno’s shares rose as much as 15.8 % just after the rumor was released by Bloomerg. Here is the first version […]

June 4, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Jun 2015

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Last week, Biotech Entrepreneurs gathered in Berlin for the Charité Entrepreneurship Summit 2015. As a spectator, I’ll bring you the most important lessons to take on board from successful entrepreneurs. The First speaker was James Sabry, Senior VP at Genentech, which I already interviewed on the strategy of Genentech/Roche. The Californian entrepreneur, who founded the NASDAQ-listed company Cytokinetics before joining Genentech, gave […]

June 4, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 3 Jun 2015

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Apitope’s peptide to take on Haemophilia A

Kurma Partners announces the launch of its third fund Kurma Diagnostics

An Easy Solution to Lower the Time and Costs of Clinical Trials

Biosimilars will land in Poland thanks to a European loan

Review: The Emerging Field of Bioluminescence

NuCana’s potent anti-cancer completed Phase I/II

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Novartis declines Gamida’s buyout deal for the second time

MorphoSys is safe and sound after the promising results of Celgene’s dumped project

[Update] AstraZeneca to buy a CAR-T expert?

Lesson to Learn from the Best Biotech Entrepreneurs: be a Pioneer!

Erytech successfully completed its Phase III to ‘starve’ cancer cells to death

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!